REGN

Regeneron Pharmaceuticals, Inc. Press Releases

$508.51
*  
10.27
1.98%
Get REGN Alerts
*Delayed - data as of Sep. 3, 2015  -  Find a broker to begin trading REGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015
9/1/2015 9:00:00 AM - PR Newswire
▼-0.29 % Price Change since this news event. The Volume Ratio is 1.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron Announces Upcoming 2015 Investor Conference Presentations
8/31/2015 9:30:00 AM - PR Newswire
▼-3.14 % Price Change since this news event. The Volume Ratio is 1.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron Reports Second Quarter 2015 Financial and Operating Results
8/4/2015 6:30:00 AM - PR Newswire
▼-9.39 % Price Change since this news event. The Volume Ratio is 3.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration
7/28/2015 1:00:00 AM - PR Newswire
▼-6.52 % Price Change since this news event. The Volume Ratio is 1.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
7/24/2015 3:17:00 PM - PR Newswire
▼-6.18 % Price Change since this news event. The Volume Ratio is 5.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia
7/24/2015 7:15:00 AM - PR Newswire
▼-9.44 % Price Change since this news event. The Volume Ratio is 1.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection
7/8/2015 10:00:00 PM - PR Newswire
▼-0.15 % Price Change since this news event. The Volume Ratio is 1.6.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2015
7/8/2015 9:30:00 AM - PR Newswire
▼-0.71 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol
6/30/2015 8:00:00 AM - PR Newswire
▲0.50 % Price Change since this news event. The Volume Ratio is 3.5.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
6/29/2015 3:00:00 PM - PR Newswire
▼-0.35 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


EYLEA® (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
6/26/2015 3:00:00 AM - PR Newswire
▼-2.07 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron Announces 2015 Winners of the Regeneron Prize for Creative Innovation
6/25/2015 8:30:00 AM - PR Newswire
▼-1.56 % Price Change since this news event. The Volume Ratio is 0.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day








FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
6/9/2015 6:30:00 PM - PR Newswire
▼-3.51 % Price Change since this news event. The Volume Ratio is 2.43.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Trading in Regeneron Common Stock Halted
6/9/2015 7:05:00 AM - PR Newswire


Trading in Regeneron Common Stock Halted
6/9/2015 7:05:00 AM - PR Newswire